Initial experience with the treatment of neurogenic detrusor overactivity with a new β-3 agonist (mirabegron) in patients with spinal cord injury
Crossref DOI link: https://doi.org/10.1038/sc.2015.195
Published Online: 2015-10-27
Published Print: 2016-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Wöllner, J
Pannek, J
Text and Data Mining valid from 2015-10-27
Article History
Received: 8 May 2015
Revised: 18 September 2015
Accepted: 1 October 2015
First Online: 27 October 2015
Competing interests
: The authors declare no conflict of interests.